3 result(s) displayed (1 - 3 of 3):

Amgen pipeline expands with oncology deal (from Corporate Dealmaker)

Amgen Inc. has deepened its presence in oncology -- a buzzing sector -- with an exclusive licensing deal with ImmunoGen Inc. (NASDAQ:IMGN), a developer of potential cancer therapies. Amgen will pay $1 million up-front and $34 million in potential milestone payments, plus royalties, to use ImmunoGen's technology to develop anticancer...

Posted on September 18, 2009 10:36 AM

Amgen has 'ugliest quarter,' looks to bounce back (from Corporate Dealmaker)

Amgen Inc. (NASDAQ:AMGN) of Thousand Oaks, Calif., reported grim first-quarter numbers late Thursday, with all major products showing revenue losses and profits slipping 7% to $1 billion. The woeful quarter raised the stakes for Amgen's osteoporosis drug denosumab, which U.S. regulators are reviewing for approval.Called D-mab for short, the...

Posted on April 24, 2009 3:16 PM

Banks tank, but big companies are selling bonds (from Corporate Dealmaker)

Reasons to be cheerful, part 3: Big companies are not so reliant on banks for borrowing, and the debt capital markets are starting to work again. That's the take-away from two trends in the news this week. The first is the ongoing pain among big banks, with busting-up Citigroup Inc....

Posted on January 15, 2009 10:30 AM